| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 54,030 | 36,500 | 26,820 | 14,240 | 0 |
| Sales Growth | +48.03% | +36.09% | +88.34% | unch | -100.00% |
| Net Income | -412,780 | 673,730 | -352,090 | -231,800 | 1,604,720 |
| Net Income Growth | -161.27% | +291.35% | -51.89% | -114.44% | +590.19% |
Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.
Fiscal Year End Date: 12/31